Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Source of hematopoietic progenitor cells determines their capacity to generate innate lymphoid cells ex vivo.
Cytotherapy. 2024 Apr;26(4):334-339. doi: 10.1016/j.jcyt.2024.01.013. Epub 2024 Feb 15.
Cytotherapy. 2024.
PMID: 38363249
Free article.
Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer.
Van der Meer JMR, Bulder I, Kuijk C, Kleijer M, Verheij MW, Omar SZ, Haverkate NJE, Dolstra H, Blom B, Hazenberg MD, Voermans C.
Van der Meer JMR, et al.
Cytotherapy. 2024 Feb;26(2):136-144. doi: 10.1016/j.jcyt.2023.11.011. Epub 2023 Dec 25.
Cytotherapy. 2024.
PMID: 38149947
Free article.
Item in Clipboard
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells.
Van der Meer JMR, Maas RJA, Guldevall K, Klarenaar K, de Jonge PKJD, Evert JSH, van der Waart AB, Cany J, Safrit JT, Lee JH, Wagena E, Friedl P, Önfelt B, Massuger LF, Schaap NPM, Jansen JH, Hobo W, Dolstra H.
Van der Meer JMR, et al.
Cancer Immunol Immunother. 2021 May;70(5):1305-1321. doi: 10.1007/s00262-020-02749-8. Epub 2020 Nov 3.
Cancer Immunol Immunother. 2021.
PMID: 33140189
Free PMC article.
Item in Clipboard
Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia.
de Jonge PKJD, van Hauten PMM, Janssen LD, de Goede AL, Berrien-Elliott MM, van der Meer JMR, Mousset CM, Roeven MWH, Foster M, Blijlevens N, Hobo W, Fehniger TA, Jansen JH, Schaap NPM, Dolstra H.
de Jonge PKJD, et al. Among authors: van der meer jmr.
Cancer Immunol Immunother. 2023 Oct;72(10):3323-3335. doi: 10.1007/s00262-023-03492-6. Epub 2023 Jul 21.
Cancer Immunol Immunother. 2023.
PMID: 37477653
Free PMC article.
Item in Clipboard
CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice.
Van der Meer JMR, de Jonge PKJD, van der Waart AB, Geerlings AC, Moonen JP, Brummelman J, de Klein J, Vermeulen MC, Maas RJA, Schaap NPM, Hoogstad-van Evert JS, Ottevanger PB, Jansen JH, Hobo W, Dolstra H.
Van der Meer JMR, et al.
Oncoimmunology. 2021 Oct 1;10(1):1981049. doi: 10.1080/2162402X.2021.1981049. eCollection 2021.
Oncoimmunology. 2021.
PMID: 34616589
Free PMC article.
Item in Clipboard
Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients.
Hoogstad-van Evert JS, Maas RJ, van der Meer J, Cany J, van der Steen S, Jansen JH, Miller JS, Bekkers R, Hobo W, Massuger L, Dolstra H.
Hoogstad-van Evert JS, et al.
Oncotarget. 2018 Oct 5;9(78):34810-34820. doi: 10.18632/oncotarget.26199. eCollection 2018 Oct 5.
Oncotarget. 2018.
PMID: 30410679
Free PMC article.
Item in Clipboard
Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells.
Van der Meer JMR, Maas RJA, Guldevall K, Klarenaar K, De Jonge PKJD, Hoogstad-van Evert JS, van der Waart AB, Cany J, Safrit JT, Lee JH, Wagena E, Friedl P, Önfelt B, Massuger LF, Schaap NPM, Jansen JH, Hobo W, Dolstra H.
Van der Meer JMR, et al.
Cancer Immunol Immunother. 2021 Nov;70(11):3367. doi: 10.1007/s00262-021-03049-5.
Cancer Immunol Immunother. 2021.
PMID: 34524494
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite